OCREVUS SOLUTION FOR INJECTION 920MG/23ML

Roche Diagnostics GmbH (GERMANY)🇸🇬 Health Sciences Authority

Approval Date: Nov 11, 2025
Approval ID: ed85b6dd05606826
Company: Roche Diagnostics GmbH (GERMANY)
Type: Therapeutic

Approval Details

Approval Id: ed85b6dd05606826
Drug Name: OCREVUS SOLUTION FOR INJECTION 920MG/23ML
Product Name: OCREVUS SOLUTION FOR INJECTION 920MG/23ML
Approval Number: SIN17390P
Approval Date: 2025-11-11
Registrant: ROCHE SINGAPORE PTE. LTD.
Licence Holder: ROCHE SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: INJECTION, SOLUTION
Dosage: 2.2 DOSAGE AND ADMINISTRATION General Substitution by any other biological medicinal product approved in the indication requires the consent of the prescribing physician. It is important to check the product labels to ensure that the correct formulation (Ocrevus IV or Ocrevus SC) is being administered to the patient by the correct route as prescribed. Patients may start Ocrevus treatment using Ocrevus IV or SC and patients currently receiving Ocrevus IV may continue treatment with Ocrevus IV or Ocrevus SC. Ocrevus IV Premedication for infusion-related reactions Premedicate with 100 mg IV methylprednisolone (or an equivalent) approximately 30 minutes prior to each Ocrevus IV infusion (see section 2.4 Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) and with an antihistaminic drug (e.g. diphenhydramine) approximately 30–60 minutes before each infusion of Ocrevus IV to reduce the frequency and severity of infusion-related reactions. The addition of an antipyretic (e.g. acetaminophen/paracetamol) may also be considered approximately 30–60 minutes before each infusion of Ocrevus IV. Administration of Ocrevus Ocrevus IV is not intended for subcutaneous administration. Ocrevus IV is administered as an IV infusion through a dedicated line under the close supervision of an experienced healthcare professional (HCP) with access to appropriate medical support to manage severe reactions such as serious infusion-related reactions (IRRs). Ocrevus IV infusions should not be administered as an intravenous push or bolus. Use isotonic 0.9% sodium chloride solution as the infusion vehicle. In the event an IV infusion cannot be completed the same day, the remaining liquid in the infusion bag must be discarded (see section 4.1 Storage and 4.2 Special Instructions for Use, Handling and Disposal – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Observe the patient for at least one hour after the completion of the infusion (see section 2.4.1 Warnings and Precautions, General, Infusion-Related Reactions and Injection Reactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Initial Dose Ocrevus IV is administered by IV infusion as a 600 mg dose every 6 months. The initial 600 mg dose is administered as two separate IV infusions; first as a 300 mg infusion, followed 2 weeks later by a second 300 mg infusion. Subsequent Doses Subsequent doses of Ocrevus IV thereafter are administered as a single 600 mg IV infusion every 6 months (see Table 1). If patients did not experience a serious infusion-related reaction (IRR) with any previous Ocrevus IV infusion, a shorter (2-hour) infusion can be administered for subsequent doses (see Table 1, Option 2) (see sections 2.6.1 Undesirable Effects, Clinical Trials and 3.1.2 Clinical/Efficacy Studies – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). A minimum interval of 5 months should be maintained between each dose of Ocrevus. <img src="/TGIF/Ocrevus920mg-Table1.png" alt="Ocrevus 920 mg Dosage Table 1" /> Infusion Adjustments during Treatment: No dose reductions of Ocrevus IV are recommended. In case of infusion-related reactions (IRRs) during any infusion, see the following adjustments. Additional information on IRRs can be found in section 2.4.1 Warnings and Precautions, General, Infusion-Related Reactions and Injection Reactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Life-threatening IRRs Immediately stop Ocrevus IV if there are signs of a life-threatening or disabling infusion-related reaction during an infusion, such as acute hypersensitivity or acute respiratory distress syndrome. The patient should receive appropriate supportive treatment. Permanently discontinue Ocrevus IV in these patients. Severe IRRs If a patient experiences a severe IRR or a complex of flushing, fever, and throat pain symptoms, the infusion should be interrupted immediately and the patient should receive symptomatic treatment. The infusion should be restarted only after all symptoms have resolved. The initial infusion rate at restart should be half of the infusion rate at the time of onset of the reaction. Mild to Moderate IRRs If a patient experiences a mild to moderate IRR (e.g. headache), the infusion rate should be reduced to half the rate at the onset of the event. This reduced rate should be maintained for at least 30 minutes. If tolerated, the infusion rate may then be increased according to the patient’s initial infusion schedule. See section 2.4.1 Warnings and Precautions, General, Infusion-Related Reactions and Injection Reactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information for full description of symptoms associated with IRRs. Ocrevus SC Premedication for injection reactions Premedicate orally with 20 mg dexamethasone (or equivalent) and an antihistaminic drug (e.g., desloratadine) shortly before each Ocrevus SC administration (see section 2.4 Warnings and Precautions, General, Infusion-Related Reactions and Injection Reactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) to reduce the risk of local and systemic injection reactions. The administration of an antipyretic (e.g., acetaminophen/paracetamol) may also be considered shortly before each Ocrevus SC administration. Administration of Ocrevus SC Ocrevus SC is not intended for intravenous administration. Ocrevus SC must be administered as a subcutaneous injection only, under the supervision of an HCP (see section 4.2 Special Instructions for Use, Handling and Disposal – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Prior to administration, remove Ocrevus SC from refrigeration and allow the solution to come to room temperature. For the initial dose, post-injection monitoring with access to appropriate medical support to manage any severe injection reactions, for at least one hour after injection is recommended. For subsequent doses, the suitable administration setting (e.g., clinic or home) and post-injection monitoring is at the treating physician’s discretion. Administer 23 mL (920 mg) of Ocrevus SC solution subcutaneously in the abdomen in approximately 10 minutes. Use of a SC infusion set (e.g., winged/butterfly) is recommended. DO NOT administer any residual hold-up volume remaining in the SC infusion set to the patient. The injection site should be the abdomen, except for 2 inches (5 cm) around the navel. Ocrevus SC injections should not be administered into areas where the skin is red, bruised, tender or hard, or areas where there are moles or scars. Dose and schedule Ocrevus SC is administered as a 920 mg subcutaneous injection every 6 months. No division of the initial dose or subsequent doses into separate administrations is required. A minimum interval of 5 months should be maintained between each dose of Ocrevus. Delayed or Missed Doses If a planned dose of Ocrevus is missed, it should be administered as soon as possible; do not wait until the next planned dose. The treatment interval of 6 months (with a minimum of 5 months) for Ocrevus should be maintained between doses. 2.2.1 Special Dosage Instructions Pediatric Use The safety and efficacy of Ocrevus in children and adolescents (<18 years) has not been studied. Geriatric Use The safety and efficacy of Ocrevus in patients ≥55 years of age has not been studied. Renal Impairment The safety and efficacy of Ocrevus in patients with renal impairment has not been formally studied. A change in dose is not expected to be required for patients with renal impairment (see section 2.5.6 Use in Special Populations, Renal Impairment and 3.2.5 Pharmacokinetics in Special Populations, Renal Impairment – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic Impairment The safety and efficacy of Ocrevus in patients with hepatic impairment has not been formally studied. A change in dose is not expected to be required for patients with hepatic impairment (see section 2.5.7 Use in Special Populations, Hepatic Impairment and 3.2.5 Pharmacokinetics in Special Populations, Hepatic Impairment – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Route Of Administration: SUBCUTANEOUS
Indication Info: 2.1 THERAPEUTIC INDICATION(S) Ocrevus is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features, to reduce the frequency of clinical relapses and delay the progression of physical disability. Ocrevus is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) with imaging features characteristic of inflammatory activity to delay progression of physical disability.
Contraindications: 2.3 CONTRAINDICATIONS <ul> <li>Hypersensitivity to ocrelizumab or to any of the excipients.</li> <li>Severe active infection until resolution (see Section 2.4 Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> <li>Patients with severely immunocompromised state (see Section 2.4 Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> </ul>

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Nov 11, 2025

Approval ID

ed85b6dd05606826

Type

Therapeutic

Back to HSA Approvals